Nicotine ameliorates impairment of working memory in methamphetamine-treated rats

Behavioural Brain Research

Volumn 220, Issue 1, 2011, Pages 159-163

  Mizoguchi, Hiroyuki ^a,b   Ibi, Daisuke ^b,c   Takase, Fumiaki ^b   Nagai, Taku ^c   Kamei, Hiroyuki ^d   Toth, Erika ^c   Sato, Jun ^a   Takuma, Kazuhiro ^b,e   Yamada, Kiyofumi ^b,c,f  

^a NAGOYA UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d MEIJO UNIVERSITY   (Japan)

^e OSAKA UNIVERSITY   (Japan)

^f JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Methamphetamine; Nicotine; Psychosis; Working memory

Indexed keywords

METHAMPHETAMINE; NICOTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; MALE; MAZE TEST; MEMORY DISORDER; MENTAL PERFORMANCE; MENTAL TASK; NONHUMAN; PRIORITY JOURNAL; RAT; SPATIAL MEMORY; TASK PERFORMANCE; WORKING MEMORY;

ANIMALS; ATTENTION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FOOD DEPRIVATION; MALE; MAZE LEARNING; MEMORY DISORDERS; MEMORY, SHORT-TERM; METHAMPHETAMINE; NICOTINE; NICOTINIC AGONISTS; RATS; RATS, WISTAR; SPATIAL BEHAVIOR; SYMPATHOMIMETICS; TIME FACTORS;

EID: 79951953399     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2011.01.036     Document Type: Article

References (35)

1. Seiden L.S., Sabol K.E., Ricaurte G.A. Amphetamine: effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol 1993, 33:639-677.
2. Nakajima A., Yamada K., Nagai T., Uchiyama T., Miyamoto Y., Mamiya T., et al. Role of tumor necrosis factor-α in methamphetamine-induced drug dependence and neurotoxicity. J Neurosci 2004, 24:2212-2225.
3. Mizoguchi H., Yamada K., Niwa M., Mouri A., Mizuno T., Noda Y., et al. Reduction of methamphetamine-induced sensitization and reward in matrix metalloproteinase-2 and -9-deficient mice. J Neurochem 2007, 100:1579-1588.
4. Simon S.L., Dacey J., Glynn S., Rawson R., Ling W. The effect of relapse on cognition in abstinent methamphetamine abusers. J Subst Abuse Treat 2004, 27:59-66.
5. Nordahl T.E., Salo R., Leamon M. Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: a review. J Neuropsychiatry Clin Neurosci 2003, 15:317-325.
6. Nagai T., Takuma K., Dohniwa M., Ibi D., Mizoguchi H., Kamei H., et al. Repeated methamphetamine treatment impairs spatial working memory in rats: reversal by clozapine but not haloperidol. Psychopharmacology (Berl) 2007, 194:21-32.
7. Meltzer H.Y., McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999, 25:233-255.
8. Woodward N.D., Purdon S.E., Meltzer H.Y., Zald D.H. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 2005, 8:457-472.
9. Tamminga C.A. The neurobiology of cognition in schizophrenia. J Clin Psychiatry 2006, 67:9-13.
10. Hefco V., Yamada K., Hefco A., Hritcu L., Tiron A., Nabeshima T. Role of the mesotelencephalic dopamine system in learning and memory processes in the rat. Eur J Pharmacol 2003, 475:55-60.
11. Hefco V., Yamada K., Hefco A., Hritcu L., Tiron A., Olariu A., et al. Effects of nicotine on memory impairment induced by blockade of muscarinic, nicotinic and dopamine D2 receptors in rats. Eur J Pharmacol 2003, 474:227-232.
12. Heishman S.J., Kleykamp B.A., Singleton E.G. Meta-analysis of the acute effects of nicotine and smoking on human performance. Psychopharmacology (Berl). 2010, 210:453-469.
13. Kumari V., Postma P. Nicotine use in schizophrenia: the self medication hypotheses. Neurosci Biobehav Rev 2005, 29:1021-1034.
14. Newhouse P.A., Potter A., Levin E.D. Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics. Drugs Aging 1997, 11:206-228.
15. White H.K., Levin E.D. Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer's disease. Psychopharmacology 1999, 143:158-165.
16. Glassman A.H. Cigarette smoking: implications for psychiatric illness. Am J Psychiatry 1993, 150:546-553.
17. Ziedonis D.M., George T.P. Schizophrenia and nicotine use: report of a pilot smoking cessation program and review of neurobiological and clinical issues. Schizophr Bull 1997, 23:247-254.
18. Adler L.E., Hoffer L.J., Griffith J., Waldo M.C., Freedman R. Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biol Psychiatry 1992, 32:607-616.
19. Mizoguchi H., Arai S., Koike H., Ibi D., Kamei H., Nabeshima T., et al. Therapeutic potential of nicotine for methamphetamine-induced impairment of sensorimotor gating: involvement of pallidotegmental neurons. Psychopharmacology (Berl) 2009, 207:235-243.
20. George T.P., Sernyak M.J., Ziedonis D.M., Woods S.W. Effects of clozapine on smoking in chronic schizophrenic outpatients. J Clin Psychiatry 1995, 56:344-346.
21. McEvoy J.P., Freudenreich O., Wilson W.H. Smoking and therapeutic response to clozapine in patients with schizophrenia. Biol Psychiatry 1999, 46:125-129.
22. Seamans J.K., Phillips A.G. Selective memory impairments produced by transient lidocaine-induced lesions of the nucleus accumbens in rats. Behav Neurosci 1994, 1108:456-468.
23. Volkow N.D., Chang L., Wang G.J., Fowler J.S., Leonido-Yee M., Franceschi D., et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 2001, 158:377-382.
24. Kamei H., Nagai T., Nakano H., Togan Y., Takayanagi M., Takahashi K., et al. Repeated methamphetamine treatment impairs recognition memory through a failure of novelty-induced ERK1/2 activation in the prefrontal cortex of mice. Biol Psychiatry 2006, 59:75-84.
25. Nagai T., Takuma K., Kamei H., Ito Y., Nakamichi N., Ibi D., et al. Dopamine D1 receptors regulate protein synthesis-dependent long-term recognition memory via extracellular signal-regulated kinase 1/2 in the prefrontal cortex. Learn Mem 2007, 14:117-125.
26. Mizoguchi H., Yamada K., Mouri A., Niwa M., Mizuno T., Noda Y., et al. Role of matrix metalloproteinase (MMP) and tissue inhibitor of MMP (TIMP) in methamphetamine-induced behavioral sensitization and reward: implications for dopamine receptor downregulation and dopamine release. J Neurochem 2007, 102:1548-1560.
27. Nagai T., Kamei H., Dohniwa M., Takayanagi M., Suzuki M., Matsuya T., et al. Involvement of hippocampal extracellular signal-regulated kinase 1/2 in spatial working memory in rats. Neuroreport 2006, 17:1453-1457.
28. Raybuck J.D., Gould T.J. Extracellular signal-regulated kinase 1/2 involvement in the enhancement of contextual fear conditioning by nicotine. Behav Neurosci 2007, 121:1119-1124.
29. Dani J.A., De Biasi M. Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav 2002, 70:439-446.
30. Mihailescu S., Guzmán-Marín R., Drucker-Colín R. Nicotine stimulation of dorsal raphe neurons: effects on laterodorsal and pedunculopontine neurons. Eur Neuropsychopharmacol 2001, 11:359-366.
31. Herman A.I., Sofuoglu M. Cognitive effects of nicotine: genetic moderators. Addict Biol 2010, 15:250-265.
32. Ito Y., Takuma K., Mizoguchi H., Nagai T., Yamada K. A novel azaindolizinone derivative ZSET1446 (spiro[imidazo[1,2-a]pyridine-3,2-indan]-2(3H)-one) improves methamphetamine-induced impairment of recognition memory in mice by activating extracellular signal-regulated kinase 1/2. J Pharmacol Exp Ther 2007, 320:819-827.
33. Mizoguchi H., Takuma K., Fukakusa A., Ito Y., Nakatani A., Ibi D., et al. Improvement by minocycline of methamphetamine-induced impairment of recognition memory in mice. Psychopharmacology (Berl) 2008, 196:233-241.
34. Acri J.B., Brown K.J., Saah M.I., Grunberg N.E. Strain and age differences in acoustic startle responses and effects of nicotine in rats. Pharmacol Biochem Behav 1995, 50:191-198.
35. Schreiber R., Dalmus M., De Vry J. Effects of alpha 4/beta 2- and alpha 7-nicotine acetylcholine receptor agonists on prepulse inhibition of the acoustic startle response in rats and mice. Psychopharmacology (Berl) 2005, 182:214-219.